Article Information
History
- June 8, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- SEV COVID trial group,
- Budha O Singh1,
- Bikram Moirangthem1,
- Prasan Kumar Panda1,*,
- Yogesh Arvind Bahurupi2,
- Sarama Saha3,
- Girraj Saini4,
- Minakshi Dhar1,
- Mukesh Bairwa1,
- Venkatesh Srinivasa Pai1,
- Ankit Agarwal5,
- Girish Sindhwani6,
- Shailendra Handu7 and
- Ravikant8
- 1Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
- 2Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
- 3Biochemistry, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
- 4Nursing, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
- 5Anesthesia and Critical Care Medicne, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
- 6Pulmonary Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
- 7Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
- 8Director, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India
- ↵*Corresponding Author
: Prasan Kumar Panda, Asst. Professor, Dept. of Internal Medicine, Sixth Floor, College Block, All India Institute of Medical Sciences (AIIMS), Rishikesh, India, 249203, Mob: +91-9868999488, Email: motherprasanna{at}rediffmail.com
Posted June 08, 2021.
Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial)
